Brian Powl - 27 Sep 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Thomas Doyle, Attorney-in-fact for Brian Powl
Issuer symbol
KURA
Transactions as of
27 Sep 2025
Transactions value $
-$79,505
Form type
4
Filing time
29 Sep 2025, 19:30:10 UTC
Previous filing
28 Jan 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Powl Brian T. Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO Thomas Doyle, Attorney-in-fact for Brian Powl 29 Sep 2025 0001934232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +48.9K +81.95% $0.00 109K 27 Sep 2025 Direct
transaction KURA Common Stock Sale -$79.5K -8.89K -8.19% $8.94 99.7K 29 Sep 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25.